GSK Share PerformanceMore
|52 week high||1,724.5 22/06/17|
|52 week low||1,294.0 21/11/17|
|52 week change||-210.5 (-13.89%)|
|4 week volume||234,792,399 27/10/17|
Latest News« previous» nextMore
22/11/2017 - 08:23 StockMarketWire
ViiV Healthcare, the global specialist HIV company, majority-owned by GlaxoSmithKline, with Pfizer and Shionogi Limit...
22/11/2017 - 07:00 RNS
RNS Number: 1659X GlaxoSmithKline PLC 21 November 2017 PRESS RELEASE Juluca (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection London, 21 November 2017 - ViiV Healthcare, the global specialist HIV company, majority...
21/11/2017 - 14:21 RNS
RNS Number: 1339X GlaxoSmithKline PLC 21 November 2017 GlaxoSmithKline plc GSK publishes provisional dividend dates GSK announces the following dividend dates for 2017 and 2018: Results announcement date Ex-dividend date* Record date Last date for DRIP elections Payment date Q4 2017 7 February 2018 22 February 2018 23 February 2018 20 March 2018...
16/11/2017 - 10:10 StockMarketWire
Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price ta...
16/11/2017 - 07:00 RNS
RNS Number: 6797W GlaxoSmithKline PLC 16 November 2017 Issued: 16 November 2017, London UK - LSE Announcement Trelegy Ellipta once-daily single inhaler triple therapy gains marketing authorisation in Europe for the treatment of COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Co...
10/11/2017 - 13:15 RNS
RNS Number: 2011W GlaxoSmithKline PLC 10 November 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market partic...
09/11/2017 - 17:00 RNS
RNS Number: 1021W GlaxoSmithKline PLC 09 November 2017 BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris . Date: 09 November 2017 Name of applicant: GlaxoSmithKline plc Name of scheme: GlaxoSmithKline Share Option Plan - Ordinary Shares Period of return: F...
09/11/2017 - 15:04 Interactive Investor
They've been through the mill this year, losing almost 60% of their value, but Graeme Evans has found an expert backing...
|Dividend yield||6.13 %|
Latest discussion posts More
“OK, some good comments there re the dividend question, thanks. I had not read the Q3 earning call transcript. I note the phrase: "The Board intends to maintain the dividend FOR ...”▼
“ Today's RNS suggests Juluca approval marks a significant step forward in HIV-1 treatment, more signs that GSK is getting some things right in the way it conducts its core ...”▼
“ViiV Healthcare, the global specialist HIV company, majority-owned by GlaxoSmithKline, with Pfizer and Shionogi Limited as shareholders, today announced that the US Food and ...”▼
Codes & Symbols
|Symbols||GSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment